Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis

[1]  M. Korbonits,et al.  Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms , 2020, Endocrine reviews.

[2]  J. Bertherat,et al.  Pangenomic Classification of Pituitary Neuroendocrine Tumors. , 2019, Cancer cell.

[3]  A. Beckers,et al.  GENETICS IN ENDOCRINOLOGY: Somatic and germline mutations in the pathogenesis of pituitary adenomas. , 2019, European journal of endocrinology.

[4]  A. Paetau,et al.  Genetic and Epigenetic Characterization of Growth Hormone–Secreting Pituitary Tumors , 2019, Molecular Cancer Research.

[5]  Paul P. S. Wang,et al.  The Genomic Landscape of Sporadic Prolactinomas , 2019, Endocrine Pathology.

[6]  T. Strom,et al.  Driver mutations in USP8 wild-type Cushing’s disease , 2019, Neuro-oncology.

[7]  F. Faucz,et al.  Large Genomic Aberrations in Corticotropinomas Are Associated With Greater Aggressiveness. , 2019, The Journal of clinical endocrinology and metabolism.

[8]  P. Rucci,et al.  Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. , 2019, European journal of endocrinology.

[9]  P. Chanson,et al.  Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability , 2018, Front. Endocrinol..

[10]  S. Yin,et al.  Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up. , 2018, World neurosurgery.

[11]  Hai Yan,et al.  Identification of recurrent USP48 and BRAF mutations in Cushing’s disease , 2018, Nature Communications.

[12]  B. Fox,et al.  The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes , 2018, Clinical Cancer Research.

[13]  P. Chanson,et al.  Genomic Alterations and Complex Subclonal Architecture in Sporadic GH-Secreting Pituitary Adenomas , 2018, The Journal of clinical endocrinology and metabolism.

[14]  N. Inoshita,et al.  The 2017 WHO classification of pituitary adenoma: overview and comments , 2018, Brain Tumor Pathology.

[15]  M. Elsensohn,et al.  Centralization errors in comparative genomic hybridization array analysis of pituitary tumor samples , 2018, Genes, chromosomes & cancer.

[16]  C. Raftopoulos,et al.  Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. , 2017, European journal of endocrinology.

[17]  F. Borson‐Chazot,et al.  Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five‐Tiered Classification , 2017, The Journal of clinical endocrinology and metabolism.

[18]  R. Beroukhim,et al.  Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors , 2017, Endocrinology.

[19]  S. Elledge,et al.  Aneuploidy in Cancer: Seq-ing Answers to Old Questions , 2017 .

[20]  R. Beroukhim,et al.  Landscape of Genomic Alterations in Pituitary Adenomas , 2016, Clinical Cancer Research.

[21]  Baofeng Lian,et al.  The genome-wide mutational landscape of pituitary adenomas , 2016, Cell Research.

[22]  T. Wieland,et al.  Mutations in the deubiquitinase gene USP8 cause Cushing's disease , 2014, Nature Genetics.

[23]  N. Karavitaki,et al.  Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. , 2013, European journal of endocrinology.

[24]  G. McVean,et al.  Whole-exome sequencing studies of nonfunctioning pituitary adenomas. , 2013, The Journal of clinical endocrinology and metabolism.

[25]  D. Figarella-Branger,et al.  A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up , 2013, Acta Neuropathologica.

[26]  P. Chanson,et al.  Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumors , 2011, Brain pathology.

[27]  Yan Zeng,et al.  Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior , 2010, Journal of Neuro-Oncology.

[28]  B. Scheithauer,et al.  P53 Gene Mutations in Pituitary Carcinomas , 2007, Endocrine pathology.

[29]  W. Chung,et al.  Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission , 2007, Pituitary.

[30]  R. Weil,et al.  Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization , 2005, Genes, chromosomes & cancer.

[31]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[32]  W. Farrell,et al.  Prediction of recurrence of nonfunctioning pituitary tumours by loss of heterozygosity analysis , 2004, Clinical endocrinology.

[33]  A. Jauch,et al.  Chromosomal aberrations in sporadic pituitary tumors , 2001, International journal of cancer.

[34]  B. Scheithauer,et al.  H-ras mutations in human pituitary carcinoma metastases. , 1994, The Journal of clinical endocrinology and metabolism.

[35]  A. Amon,et al.  Context is everything: aneuploidy in cancer , 2019, Nature Reviews Genetics.

[36]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. , 2018, European journal of endocrinology.

[37]  K. Schluens,et al.  Genomic Instability in Pituitary Adenomas , 2004, Pituitary.

[38]  R. Mains,et al.  Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. , 1980, Endocrine reviews.